IPMA TABLETS

(Iron Polymaltose 100 mg)

COMPOSITION

Each tablet provides 100 mg elemental iron as iron(III)-hydroxide polymaltose complex. The amount of complex and excipients are according to the approved product formula.

DESCRIPTION

IPMA Tablets are an oral iron preparation used to replenish body iron stores. Iron polymaltose is a stable macromolecular complex of iron(III)-hydroxide and polymaltose.

PHARMACOLOGICAL ACTION

Iron is an essential constituent of haemoglobin and myoglobin and participates in several enzyme systems. Following oral administration, absorbed iron is used for haemoglobin synthesis or stored as ferritin. Iron polymaltose provides iron for correction of deficiency. Absorption varies with iron status and physiological requirements.

INDICATIONS

Treatment of iron deficiency and iron-deficiency anaemia in adults and adolescents when oral ferrous iron salts are not tolerated or otherwise unsuitable. Prevention of iron deficiency in individuals at increased risk, when clinically indicated. Investigate the cause of anaemia before treatment.

DOSAGE AND ADMINISTRATION

Adults and adolescents aged 12 years and above: for treatment of iron deficiency, 1-2 tablets daily (100-200 mg elemental iron), or as directed by a physician. For prevention in high-risk patients, 1 tablet daily or as advised. Dosage and duration depend on laboratory-confirmed deficiency and response. Take during or immediately after food; swallow the tablet whole with water if film-coated.

DURATION OF TREATMENT

Treatment may be required for several months. Continue as directed after haemoglobin normalizes to restore iron reserves. Monitor haemoglobin, ferritin and other appropriate iron indices. Do not increase the dose or continue long-term without review.

CONTRAINDICATIONS

Hypersensitivity to iron polymaltose or product excipients; iron overload, including haemochromatosis and haemosiderosis; disturbances of iron utilization; anaemia not caused by iron deficiency, such as haemolytic anaemia or vitamin B12-deficiency megaloblastic anaemia.

WARNINGS AND PRECAUTIONS

Confirm iron deficiency and assess its underlying cause, including possible blood loss. Avoid unsupervised simultaneous use of other iron-containing products. Use with medical advice in patients with infection, inflammation, malignancy, liver or kidney disease. Gastrointestinal symptoms may occur. Dark stool can occur and is usually harmless but may mask visible signs of gastrointestinal bleeding.

USE IN CHILDREN

This tablet presentation is not recommended for children under 12 years of age without specialist assessment. Liquid formulations may be more suitable when a lower dose is required. Accidental ingestion of iron preparations by children requires urgent medical assessment.

DRUG INTERACTIONS

Tell the healthcare professional about all medicines and supplements. Concomitant parenteral iron is generally not recommended because oral iron absorption may be reduced. Studies with iron polymaltose have not demonstrated clinically significant interactions with tetracycline or aluminium hydroxide, but review the complete medication regimen.

PREGNANCY

Iron requirements increase in pregnancy. Iron polymaltose may be prescribed to treat or prevent documented deficiency after medical assessment. A healthcare professional should determine the dose and duration, considering haemoglobin and iron stores.

LACTATION

Iron is naturally present in breast milk. Available information on transfer from iron polymaltose treatment is limited. Use during breastfeeding after consultation with a healthcare professional.

ADVERSE REACTIONS

The most commonly reported adverse effects include dark or discoloured stools, nausea, abdominal pain or discomfort, indigestion, bloating, constipation, diarrhoea and occasionally vomiting. Headache or skin reactions, including itching, rash or urticaria, may occur. Discontinue and seek urgent help for breathing difficulty, facial swelling or severe allergic reaction.

OVERDOSAGE

Do not exceed the prescribed dose. In case of accidental ingestion or suspected overdose, seek immediate medical advice or contact an emergency service, especially if a child may have swallowed tablets. Do not induce vomiting unless instructed by a medical professional. Management is supportive and guided by clinical assessment.

EFFECT ON DRIVING AND MACHINERY

Iron polymaltose is not expected to have a clinically important effect on the ability to drive or operate machinery.

STORAGE CONDITIONS

Store in a cool, dry place away from moisture and direct sunlight. Follow the storage temperature on the approved pack. Keep out of the sight and reach of children. Do not use after the expiry date.

PRESENTATION

IPMA Tablets 100 mg: packs of 10 tablets and 3 x 10 tablets.

MANUFACTURED BY

Vega Pharmaceuticals (Pvt.) Ltd.